Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis
Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients Oakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:
United States Dennis Mcnamara Trevor Burns Heart Failure Research Company Phase University Of Pittsburgh Medical Center
Source: finanznachrichten.de